Sam Chun Dang Pharm Reschedules Overseas NDR and Updates Pipeline Progress

Sam Chun Dang Pharm will hold an overseas NDR in Hong Kong and Singapore from June 8 to 9, 2026 for global investors.
The IR aims to share progress on key pipeline assets including oral insulin S-PASS, oral semaglutide, and biosimilars, along with global partnering updates.
The event is sponsored by Korea Investment & Securities and does not involve any capital raising or share issuance.
[AI Summary]This IR is a routine corporate communication event without capital changes, thus limited direct impact on short-term stock price. It serves to maintain investor confidence in the company's pipeline progress.